Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Jiangxi Institute of Gastroenterology and Hepatology, Nanchang 330006, China.
Biomed Res Int. 2020 Mar 20;2020:7170457. doi: 10.1155/2020/7170457. eCollection 2020.
Liver cirrhosis is the terminal stage of most chronic liver conditions, with a high risk of mortality. Careful evaluation of the prognosis of cirrhotic patients and providing precise management are crucial to reduce the risk of mortality. Although the liver biopsy and hepatic venous pressure gradient (HVPG) can efficiently evaluate the prognosis of cirrhotic patients, their application is limited due to the invasion procedures. Child-Pugh score and the model for end-stage liver disease (MELD) score had been widely used in the assessment of cirrhotic prognosis, but the defects of subjective variable application in Child-Pugh score and unsuitability to all phases of liver cirrhosis in MELD score limit their prognostic values. In recent years, continuous efforts have been made to investigate the prognostic value of body fluid biomarkers for cirrhotic patients, and promising results have been reported. Since the collection of fluid specimens is easy, noninvasive, and repeatable, fluid biomarkers can be ideal indicators to predict the prognosis of cirrhosis. Here, we reviewed noninvasive fluid biomarkers in different prognostic functions, including the prediction of survival and complication development.
肝硬化是大多数慢性肝病的终末期阶段，死亡率较高。仔细评估肝硬化患者的预后并提供精确的管理对于降低死亡率至关重要。尽管肝活检和肝静脉压力梯度 (HVPG) 可有效地评估肝硬化患者的预后，但由于侵袭性程序，其应用受到限制。Child-Pugh 评分和终末期肝病模型 (MELD) 评分已广泛用于评估肝硬化的预后，但 Child-Pugh 评分中主观变量应用的缺陷和 MELD 评分不适用于肝硬化的所有阶段限制了它们的预后价值。近年来，人们一直在努力研究体液生物标志物对肝硬化患者的预后价值，并报告了有希望的结果。由于采集体液标本既容易又无创且可重复，因此体液标志物可以成为预测肝硬化预后的理想指标。在这里，我们回顾了不同预后功能的非侵入性体液生物标志物，包括对生存和并发症发展的预测。
